On Feb. 6, 2006, Sanofi pasteur announced it had delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.

Sanofi pasteur shipped 15,000 investigational doses of a vaccine to protect against the H5N1 influenza strain to the U.S. National Institutes of Health (NIH). Prepared with different levels of antigen, the investigational doses was used in the NIH’s clinical studies to determine the optimal formulation of the vaccine.